Clinical Trials on Chronic Myeloid Leukemia (for Part B and C)

Total 3205 results

Novartis Pharmaceuticals

Recruiting

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START)

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Singapore, France, Germany, United Arab Emirates, Greece, Italy, Czechia, Hungary, United States, Oman, Malaysia, Korea, Republic of, Turkey, Bulgaria, Canada, Slovakia, United Kingdom, Argentina, Jordan, Romania, South Africa, Sw... and more
University Hospital, Antwerp

Unknown

Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma

Acute Myeloid Leukemia | Multiple Myeloma | Chronic Myeloid Leukemia

Belgium
Center for International Blood and Marrow Transplant...
Sanofi; Genzyme, a Sanofi Company

Completed

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Hodgkin's Disease | Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member

United States
National Cancer Institute (NCI)

Not yet recruiting

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell | B-Cell Chronic Lymphocytic Leukemia | B-Lymphocytic Leukemia, Chronic

United States
M.D. Anderson Cancer Center

Active, not recruiting

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic/Myeloproliferative Neoplasm | Refractory Myelodysplastic/Myeloproliferative Neoplasm

United States
AstraZeneca

Recruiting

Retention Rate of Acalabrutinib in a Non-interventional Setting (RETAIN)

Chronic Lymphocytic Leukaemia (CLL)

Germany
French Innovative Leukemia Organisation

Terminated

Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL (BOMP)

B-cell Chronic Lymphocytic Leukemia (B-CLL)

France
Genzyme, a Sanofi Company
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

Completed

Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia

B-Cell Chronic Lymphocytic Leukemia (B-CLL)

United Kingdom, Belgium, France, United States, Czech Republic, Serbia
The Korean Society of Blood and Marrow Transplantation
Chonbuk National University Hospital; Samsung Medical Center; Seoul St. Mary's... and other collaborators

Terminated

Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants

Myelodysplastic Syndromes | Leukemia, Myeloid, Chronic-Phase | Acute Leukemia in Remission | Leukemia, Myeloid, Accelerated-Phase

Korea, Republic of
National Cancer Institute (NCI)

Completed

3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia and other conditions

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS) | Chronic Myeloid Leukemia (CML)

United States
National Cancer Institute (NCI)

Terminated

17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Versailles Hospital

Recruiting

Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW) (ACTIW)

Leukemia, Myeloid, Chronic-Phase

France
Children's Hospital of Soochow University

Recruiting

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

AML, Childhood | C-KIT Mutation | Refractory AML | Relapse/Recurrence | Core Binding Factor Acute Myeloid Leukemia

China
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Improving Blood Stem Cell Collection and Transplant Procedures

Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia | Myelodysplastic Syndrome (MDS) | CLL (Chronic Lymphocytic Leukemia) | CML (Chronic Myelogenous Leukemia

United States
Bristol-Myers Squibb

Recruiting

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy

Multiple Myeloma | Non-Hodgkin Lymphoma | Chronic Lymphocytic Leukaemia

Belgium
Marlise Luskin, MD
Novartis

Recruiting

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

B-cell Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL

United States
Vilnius University

Completed

High-dose Methylprednisolone and Rituximab in High Risk B-CLL (LT-CLL-001)

Chronic B-Lymphocytic Leukemia

Lithuania
Institut Bergonié
Novartis

Terminated

Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response (MIM)

Leukemia, Myeloid, Chronic-Phase

France
Versailles Hospital

Completed

Pioglityazone and Imatinib for CML Patients (ACTIM)

Leukemia, Myeloid, Chronic-Phase

France
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Completed

Therapy of Early Chronic Phase CML With Gleevec

Leukemia, Myeloid, Chronic-Phase

United States
Amgen

Active, not recruiting

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia

United States, Australia, Japan, Germany, Canada
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Adult Acute Myeloid Leukemia in Remission | Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Previously Treated Myelodysplastic Syndromes | Relapsing Chronic Myelogenous Leukemia | Refractory Anemia With Excess Blasts | Refractory Anemia With Excess...

United States
Washington University School of Medicine

Completed

Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

Lymphoma, Non-Hodgkin | Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Multiple Myeloma | Hodgkin Disease | Leukemia, Lymphocytic, Chronic, B-Cell

United States
Gilead Sciences
Ono Pharmaceutical Co. Ltd

Completed

Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL

Chronic Lymphocytic Leukaemia | Non Hodgkins Lymphoma

United Kingdom, France
Royal Marsden NHS Foundation Trust
Cambridge University Hospitals NHS Foundation Trust; University Hospital Plymouth...

Unknown

Tissue Collection for Biomarkers Determining Resistance to Ibrutinib (CLARITY)

Mantle Cell Lymphoma | Chronic Lymphocytic Leukaemia

United Kingdom
Niguarda Hospital

Completed

Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

Leukemia, Myeloid, Chronic-Phase

Italy
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Intra-Osseous Co-Transplant of UCB and hMSC

Myelodysplastic Syndromes | Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Myelofibrosis | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Lymphoid Malignancies | Relapsed Non-Hodgkin Lymphoma and other conditions

United States
Beth Israel Deaconess Medical Center
Genzyme, a Sanofi Company

Completed

Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Acute Lymphocytic Leukemia | Hodgkins Disease | Relapsed/Refractory Chronic Lymphocytic Leukemia | Relapsed Refractory Multiple Myeloma | Relapsed/Refractory Non Hodgkin's Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Myelofibrosis | Chronic Lymphocytic Leukemia | Adult Acute Myeloid Leukemia in Remission | Myelodysplastic Syndrome | Adult Acute Lymphoblastic Leukemia in Remission | Myeloproliferative Neoplasm | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditions

United States
University Hospital, Caen
CNRS, UMR ISTCT 6301, LDM-TEP Groupe, GIP Cyceron, Caen, France

Completed

Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies (FLUDATEP)

Untreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma Patients

France
Massachusetts General Hospital
Celgene

Completed

IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
European Society for Blood and Marrow Transplantation
Amgen

Withdrawn

Palifermin After Haploidentical PBSCT (KGF Haplo Allo)

Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Acute Leukaemia | Non-Hodgkin's Lymphoma or Hodgkin's Disease | Osteomyelofibrosis

Germany
Novartis Pharmaceuticals

Completed

Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T315I Mutation - a Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Chronic Myeloid Leukemia With T315I Mutation

Switzerland
Fred Hutchinson Cancer Research Center/University...

Withdrawn

Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia
Genzyme, a Sanofi Company

Completed

Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia

B Cell Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Therapy-Related Acute Myeloid Leukemia and other conditions

United States
National Cancer Institute (NCI)

Not yet recruiting

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory High Risk Myelodysplastic Syndrome
Masonic Cancer Center, University of Minnesota

Terminated

Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies

Follicular Lymphoma | Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin Lymphoma | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Acute Myelogenous Leukemia | Mantle-Cell Lymphoma | Chronic Myelogenous Leukemia | Prolymphocytic Leukemia | Small... and other conditions

United States
Steven E. Coutre
Bayer

Completed

Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia

Leukemia | Chronic Lymphocytic Leukemia (CLL) | Chronic Leukemia | B-cell Leukemia

United States
Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Myeloid Metaplasia | Philadelphia Chromosome-negative CML | Advanced Polycythemia

United States
St. Petersburg State Pavlov Medical University

Terminated

Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT

Myelodysplastic Syndromes | Leukemia, Chronic Myeloid | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Russian Federation
National Cancer Institute (NCI)

Terminated

Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib

Chronic Myeloid Leukemia | Adults | Chronic Phase

Italy
Prelude Therapeutics

Completed

A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

Adenoid Cystic Carcinoma | Refractory Chronic Myelomonocytic Leukemia | Relapsed/Refractory Acute Myeloid Leukemia | Relapsed/Refractory Mantle Cell Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma | Relapsed/Refractory Advanced Solid Tumors | Relapsed/Refractory Myelodysplasia | Relapsed...

United States
Novartis Pharmaceuticals

Not yet recruiting

Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation (ASC4INDIA)

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
M.D. Anderson Cancer Center

Recruiting

Off-the-shelf NK Cells + SCT for Myeloid Malignancies

Acute Myeloid Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Myeloid Malignancies

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Minimal Residual Disease | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Study on the Diagnosis and Management of CLL in Italy by GIMEMA

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type

Italy

Clinical Trials on Chronic Myeloid Leukemia (for Part B and C)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations